Meeting
2014 ASCO Annual Meeting
Intratumoral vaccination with activated allogeneic dendritic cells in patients with newly diganosed metastatic renal cell carcinoma (mRCC).
Authors
Anders Magnusson
Department of Radiology, Uppsala University, Uppsala, Sweden
Anders Magnusson , Anna Laurell , Maria Lonnemark , Einar Brekkan , Lars Adamson , Anna Tolf , Bengt Andersson , AnnaCarin Wallgren , Rolf Kiessling , Alex Karlsson-Parra
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Immunotherapy
Track
Developmental Therapeutics
Sub Track
Vaccines
Clinical Trial Registration Number
NCT01525017
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 3085)
DOI
10.1200/jco.2014.32.15_suppl.3085
Abstract #
3085
Poster Bd #
152
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
A phase II open labeled, randomized study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination compared to Montanide, in melanoma patients in complete clinical remission.
First Author: Anna C. Pavlick
Poster
2015 ASCO Annual Meeting
In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy.
First Author: Thomas Urban Marron
Poster
2024 ASCO Annual Meeting
Development of an mRNA therapeutic vaccine for virally driven Merkel cell carcinoma.
First Author: Alexander Frey
Poster
2024 ASCO Genitourinary Cancers Symposium
Multi-omic characterization of acquired resistance to immune checkpoint inhibitors in patients with metastatic renal cell carcinoma.
First Author: Eddy Saad